non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Non-hodgkin's%20lymphoma Treatment

Principles of Therapy

Indications for Initiation of Treatment in Follicular Lymphoma (FL)

  • Groupe d’Etude des Lymphomes Folliculaires (GELF) Criteria
    • ≥3 nodal sites involved, each measuring ≥3 cm in diameter
    • Any nodal/extranodal tumor mass ≥7 cm
    • Cytopenias (leukocytes <1.0 x 109/L, platelets <100 x 109/L)
    • Presence of systemic symptoms
    • Splenomegaly
    • Pleural effusion/peritoneal ascites
    • Leukemia (>5.0 x 109/L malignant cells)
  • Follicular Lymphoma International Prognostic Index (FLIPI) Criteria
    • Eastern Cooperative Oncology Group (ECOG) performance status >1
    • Serum LDH/β2-microglobulin level > upper limit of normal
    • Hemoglobin level <12 g/dL
    • ≥60 years old
    • Ann Arbor Stage III-IV
    • ≥5 nodal sites involved

Pharmacotherapy

Alkylating Agents
  • Eg Bendamustine, Chlorambucil, Cyclophosphamide, Ifosfamide, Temozolomide
  • May be used in combination with Vincristine, Prednisone, Dexamethasone, Rituximab, Procarbazine, Doxorubicin, or Fludarabine for patients with indolent noncontiguous stage II/III/IV NHL
  • Recommended as 1st line treatment for elderly patients with FL with or without Rituximab
  • Temozolomide is recommended for refractory/relapsed MF/SS with CNS involvement
  • May be given with or without corticosteroids
Bendamustine
  • May be used alone or in combination with Rituximab in the 2nd-line treatment of MCL
    • Bendamustine/Rituximab combination may be used as 2nd-line and subsequent therapy in patients with DLBCL
  • Bendamustine (+ anti-CD20 monocloncal antibody: Obinutuzumab, Ofatumumab or Rituximab) is recommended in the following:
    • 1st line treatment for CLL/SLL patients without del(17p)/TP53 mutation aged ≥65 years and younger with significant comorbidities
    • For CLL/SLL patients without del(17p)/TP53 mutation aged <65 years without signficant comorbidities
  • Alternative treatment option for 2nd-line and subsequent therapy of PTCL and ATLL
Chlorambucil
  • Treatment option for CLL/SLL patients without del(17p)/TP53 mutation who are intolerant to purine analogs or frail with significant comorbidity or aged ≥65 years and younger with significant comorbidities, given alone or in combination with Obinutuzumab
  • Recommended for relapsed/refractory MF/SS
Cyclophosphamide
  • Recommended for relapsed/refractory MF/SS 
  • Alternative 2nd-line or initial palliative intent treatment for PTCL
Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy
Axicabtagene ciloleucel
  • Recommended in the 2nd-line and subsequent treatment of patients with DLBCL
  • Used in the treatment of DLBCL arising from FL and nodal MZL, after ≥2 previous chemoimmunotherapy regimens
Tisagenlecleucel
  • Recommended in the 2nd-line and subsequent treatment of DLBCL
  • Used in the treatment of DLBCL arising from FL and nodal MZL, after ≥2 previous chemoimmunotherapy regimens
Anti-CD20 Monoclonal Antibodies
Alemtuzumab
  • Recommended for relapsed/refractory MF/SS
  • Treatment option for CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease 
  • Second-line and subsequent treatment option for PTCL patients who are against organ transplant, ATLL and for symptomatic management of T-PLL patients (IV route with or without Pentostatin) 
Brentuximab vedotin
  • Second-line and subsequent treatment option for PTCL, ATLL, ENKL and DLBCL patients, and systemic 1st-line therapy for patients with MF/SS
  • In combination with CHP is recommended for monomorphic (T-cell type) PTLD, 1st-line therapy of PTCL and initial therapy of ATLL
Ibritumomab tiuxetan
  • Treatment option for elderly or infirm patients who cannot tolerate 1st- and 2nd-line and subsequent therapy for FL
  • May be an option in the 1st-line consolidation/extended dosing and 2nd-line and subsequent treatment of FL and 1st- and 2nd line and subsequent treatment of MZL
Obinutuzumab
  • Recommended for FL patients in the 1st- and 2nd-line consolidation or extended dosing therapy and in the 2nd-line and subsequent treatment in combination with Bendamustine, CHOP or CVP, of patients with Rituximab-refractory disease
  • Treatment option for untreated CLL/SLL patients without del(17p) or TP53 mutation who are intolerant to purine analogs or aged ≥65 years and younger with significant comorbidities and for patients with relapsed/refractory disease regardless of age and comorbidities
  • Treatment option for untreated CLL/SLL patients with del(17p)/TP53 mutation
  • Approved for treatment-naive CLL patients in combination with Chlorambucil
Ofatumumab
  • Recommended in the following:
    • For CLL/SLL patients with or without del(17p)/TP53 mutation with relapsed/refractory disease regardless of age and comorbidities
    • As post 2nd-line maintenance therapy for patients with complete or partial response after relapsed or refractory CLL/SLL therapy
    • 2nd-line consolidation or extended dosing treatment for Rituximab-refractory disease of patients with recurrent MZL and previously treated with Bendamustine + Obinutuzumab
  • Needs further studies to be proven effective for patients with indolent noncontiguous stage II/III/IV NHL
Radio-labeled Anti-CD20 Monoclonal Antibodies
  • Eg Yttrium-90-Labeled Ibritumomab tiuxetan
  • Suggested for indolent noncontiguous stage II/III/IV NHL and indolent/aggressive recurrent NHL patients, without prior treatment, with or without bone marrow involvement
  • Studies have shown 60-80% response rate in relapsed/refractory NHL patients
Rituximab
  • First-line therapy for patients with indolent noncontiguous stage II/III/IV CD20-positive NHL
    • May be combined with other chemotherapeutic drugs (Bendamustine, Cladribine, Fludarabine, Cyclophosphamide, Vincristine, Prednisone, Doxorubicin, Mitoxantrone)
  • Recommended in the following:
    • For patients with indolent stage I and contiguous stage II NHL
      • Considered in patients with contraindications for radiotherapy, and for those unresponsive to other chemotherapeutic agents and interventions
    • 1st- and 2nd-line and subsequent treatment of patients with FL and for elderly or infirm patients who cannot tolerate other treatment regimens for FL and MZL
    • 1st- and 2nd-line consolidation or extended dosing therapy of patients with FL and as 1st-line extended therapy for MZL
    • 1st-line therapy of patients with splenic, extranodal (MALT) and nodal MZL and for the sequential chemoimmunotherapy of monomorphic (B-cell type) and polymorphic PTLD
    • Maintenance therapy of MCL patients after high-dose autologous stem cell rescue or less aggressive therapy
    • In combination with high-dose Methotrexate for primary CNS PTLD (B-cell type)
  • Treatment option in the following:
    • For CLL/SLL patients without del(17p)/TP53 mutation aged ≥65 years and younger with significant comorbidities or frail with significant comorbidity or intolerant to purine analogs
    • 1st-line therapy of patients with extranodal MALT and nodal MZL
    • 2nd-line/subsequent therapy of patients with MZL with longer duration of remission and for DLBCL
    • Refractory/relapsed HCL
  • Also recommended for patients with indolent NHL in relapse
    • Studies show a response rate of 40-50% in patients with indolent NHL
    • May also be combined with other chemotherapeutic drugs
  • Several studies have shown that maintenance therapy with Rituximab improves overall survival in FL patients
Antimetabolites (Folic acid/Purine/Pyrimidine Analogs)
  • Eg 2-Chlorodeoxyadenosine, Cladribine, Fludarabine, Gemcitabine, Methotrexate, Pentostatin, Pralatrexate
  • Recommended for patients with indolent noncontiguous stage II/III/IV NHL
  • Cladribine is a purine analog recommended for initial therapy of HCL and for relapsed/refractory disease with or without Rituximab 
  • Fludarabine may also be combined with Chlorambucil
  • Gemcitabine is recommended in the systemic 1st-line therapy of MF/SS
  • Methotrexate may be used as 2nd-line systemic therapy for patients with MF/SS a for DLBCL with CNS disease and for DLBCL with CNS disease
  • Pentostatin is a purine analog recommended for initial therapy and relapsed/refractory HCL disease with or without Rituximab and may be used as 2nd-line therapy for patients with MF/SS
  • Pralatrexate (preferred) and Gemcitabine are 2nd-line and subsequent therapies for patients with PTCL, and systemic 1st-line therapy for patients with MF/SS
    • Pralatrexate is also recommended for relapsed/refractory EKNL
Denileukin diftitox
  • Recombinant interleukin fusion toxin combination of interleukin-2 and diphtheria toxin
  • Studies have shown 25% objective response rate in aggressive B-cell NHL patients
Lenalidomide
  • Used in the 2nd-line treatment of MCL as monotherapy or in combination with Rituximab
  • Recommended in the 2nd-line and subsequent therapy of patients with ATLL and as an alternative 2nd-line and subsequent therapy for patients with PTCL
  • May be considered for maintenance therapy in high-risk CLL/SLL patients without del(17p)/TP53 mutation after 1st-line treatment
  • Treatment option for the following:
    • CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease and as post 2nd-line maintenance therapy in patients with complete or partial response after relapsed/refractory treatment
    • 2nd-line and subsequent treatment of patients with FL where anti-CD20 monoclonal antibody treatment is not appropriate
    • 1st-line consolidation therapy in patients aged 60-80 years with DLBCL
Other Antineoplastic Agents
  • Eg Acalabrutinib, Belinostat, Bortezomib, Copanlisib, Duvelisib, Ibrutinib, Idelalisib, Mogamulizumab, Moxetumomab pasudotox, Nivolumab, Pembrolizumab, Romidepsin, Vemurafenib, Venetoclax, Vorinostat, Zanubrutinib
  • Belinostat has been approved for the treatment of relapsed/refractory PTCL and as an alternative 2nd-line and subsequent therapy for ATLL and relapsed/refractory EKNL
  • Bortezomib may be used alone or in combination with Rituximab as 2nd-line therapy of patients with MCL or MF/SS, as 2nd-line and subsequent therapy for PTCL patients who are against organ transplant and for ATLL
  • Mogamulizumab is recommended in the 2nd-line and subsequent therapy of patients with ATLL and systemic 1st-line therapy of MF/SS
  • Moxetumomab pasudotox is recommended for progressive HCL after relapsed/refractory treatment
  • Nivolumab monotherapy or in combination with Brentuximab vedotin is a treatment option for relapsed/refractory PBML and EKNL
  • Pembrolizumab is indicated for patients with relapsed/refractory PBML, EKNL and MF/SS
  • Romidepsin is indicated for patients with cutaneous T-cell lymphoma, 2nd-line and subsequent therapy of PTCL and 1st-line systemic therapy for patients with MF/SS or in relapsed/refractory EKNL
  • Vemurafenib is recommended in relapsed/refractory HCL and progressive disease after treatment of relapsed/refractory HCL
  • Vorinostat is recommended in the systemic 1st-line therapy of MF/SS
  • Zanubrutinib is recommended in the 2nd-line treatment of patients with MCL 
  • There are ongoing studies investigating the use of these drugs for other types of cancer
Acalabrutinib
  • Recommended for untreated CLL/SLL patients without del(17p)/TP53 mutation or with relapsed/refractory disease regardless of age and comorbidities and for CLL/SLL patients with del(17p)/TP53 mutation with relapsed/refractory disease
  • Recommended in the 2nd-line treatment of patients with MCL
Copanlisib
  • Treatment option for patients in the 2nd-line and subsequent therapy of patients with refractory/relapsed FL and MZL, after 2 previous treatments
Duvelisib
  • Recommended for CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease who are frail with significant comorbidity or aged <65 years without significant comorbidities and ≥65 years and younger with significant comorbidities and those with del(17p)/TP53 mutation with relapsed/refractory disease
  • Treatment option in the 2nd-line/subsequent therapy of patients with relapsed/refractory FL and MZL, after 2 previous therapies
Ibrutinib
  • Recommended in the following:
    • Untreated CLL/SLL patients without del(17p)/TP53 mutation or with relapsed/refractory disease who are intolerant to purine analogs, frail with significant comorbidity or aged ≥65 years and younger with significant comorbidities and <65 years without significant comordities
    • Untreated CLL/SLL patients with del(17p)/TP53 mutation or with relapsed/refractory disease
    • 2nd-line systemic therapy for patients with MCL
    • 2nd-line and subsequent treatment of MZL
      • One of the preferred regimens for elderly or infirm patients who cannot tolerate other treatment regimens
  • Treatment option in the 2nd-line and subsequent treatment of non-germinal center B-cell (GCB) DLBCL and in the treatment of progressive HCL after relapsed/refractory therapy
  • Associated with transient increase in lymphocyte count, grade 2 bleeding and hypertension
Idelalisib
  • Recommended for patients with relapsed/refractory CLL/SLL with or without del(17p)/TP53 mutation regardless of age and comorbidities
  • Treatment option in the 2nd-line and subsequent therapy of patients with relapsed/refractory FL and MZL, after 2 previous treatments
Venetoclax
  • Recommended for CLL/SLL patients with or without del(17p)/TP53 mutation with relapsed/refractory disease regardless of age and comorbidities
  • Treatment option in the 2nd-line treatment of MCL
Chemotherapeutic Combinations
  • Acalabrutinib ± Obinutuzumab
    • Recommended for CLL/SLL patients without del(17p)/TP53 mutation who are intolerant to purine analogs, frail with significant comorbidity or aged ≥65 years and younger with significant comorbidity or <65 years without significant comorbidities or untreated CLL/SLL patients with del(17p)/TP53 mutation
  • Alemtuzumab ± Rituximab
    • Recommended for CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease aged ≥65 years and younger with significant comorbidities or <65 years without significant comorbidities and treatment option for untreated CLL/SLL patients with del(17p)/TP53 mutation or with relapsed/refractory disease
  • Bendamustine, Bortezomib, Rituximab
    • Treatment option for relapsed/refractory MCL
  • Bendamustine + Obinutuzumab
    • Recommended in the 1st- and 2nd-line and subsequent treatment of FL
    • Recommended in the 2nd-line and subsequent treatment of MZL in patients not previously treated with Bendamustine
  • Bendamustine + Rituximab
    • Used for patients with indolent noncontiguous stage II/III/IV NHL
    • Recommended in the 1st-line and 2nd-line and subsequent treatment of patients with FL, MZL in patients without previous treatment with Bendamustine and for CLL/SLL patients without del(17p)/TP53 mutation aged without significant comorbidities and ≥65 years and younger with significant comorbidities
    • May be used with or without Ibrutinib or Idelalisib for CLL/SLL patients without del(17p)/TP53 mutation with refractory/relapsed disease regardless of age and comorbidities
    • May be used for induction and in the 2nd-line treatment of MCL and in the 2nd-line and subsequent treatment of DLBCL
  • Chlorambucil + Rituximab
    • Recommended for CLL/SLL patients without del(17p)/TP53 mutation with refractory/relapsed disease ≥65 years and younger with significant comorbidities or frail with significant comorbidity
    • Also used in the 1st- and 2nd-line and subsequent therapy for elderly or infirm patients who cannot tolerate any treatment regimens for FL and MZL 
  • CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
    • Recommended in the 1st-line treatment for PTCL and ATLL
    • In combination with Etoposide (CHOEP) is used in the 1st-line treatment of PTCL and ATLL
    • In combination with Obinutuzumab is recommended in the 1st- and 2nd-line/subsequent treatment of FL
    • Part of the sequential chemoimmunotherapy of monomorphic and polymorphic PTLD if PET/CT scan is negative
  • CODOX-M (Cyclophosphamide, Doxorubicin, Vincristine, intrathecal Methotrexate and Cytarabine)
    • Followed by systemic Methotrexate and Rituximab, is recommended for induction therapy of patients <60 years old with low-risk BL
    • Followed by systemic Methotrexate alternating with Ifosfamide, Cytarabine, Etoposide and intrathecal Methotrexate (IVAC) + Rituximab, is recommended for induction therapy of patients <60 years with high-risk BL
  • CVP (Cyclophosphamide, Vincristine and Prednisone/Prednisolone)
    • Patients may be given Rituximab as maintenance therapy after treatment
    • In combination with Obinutuzumab is recommended in the 1st- and 2nd-line/subsequent treatment of FL
    • Treatment option for frail patients with monomorphic (T-cell type) PTLD who are intolerant of anthracyclines
  • Cyclophosphamide ± Rituximab
    • Treatment option in the 1st- and 2nd-line and subsequent therapy of elderly or infirm patients who cannot tolerate other treatment regimens for FL and MZL
  • Cytarabine + Rituximab
    • May be used in high doses for patients with relapsed BL
  • DHAX (Dexamethasone, Cytarabine, Oxaliplatin) ± Rituximab
    • Recommended in the 2nd-line and subsequent treatment of DLBCL
  • EPOCH-R (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) + Rituximab (dose-adjusted)
    • Recommended in the following:
      • 1st-line treatment for patients with primary mediastinal large B-cell lymphoma (PMBL), DLBCL, PTCL, and patients with ATLL excluding Rituximab
      • Induction therapy of patients with BL in combination with intrathecal Methotrexate
    • May also be used as 1st-line treatment in patients with DLBCL with poor LV function, for 2nd-line and subsequent treatment of DLBCL and for high-grade B-cell lymphomas (HGBL)
    • May be used as induction and 2nd-line therapy for patients with BL
  • ESHAP (Etoposide, Methylprednisolone, Cytarabine, Cisplatin) ± Rituximab
    • Recommended 2nd-line and subsequent treatment of patients with DLBCL, PTCL, ATLL and EKNL with Rituximab excluded
  • FCR (Fludarabine, Cyclophosphamide and Rituximab)
    • Recommended for patients with IGHV-mutated CLL patients without del(17p)/TP53 mutation aged <65 years without significant comorbidities or those with refractory/relapsed disease <65 years without significant comorbidities and in reduced-dose for ≥65 years old and younger with significant comorbidities
  • FC (Fludarabine, Cyclophosphamide) + Ofatumumab
    • Recommended for CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease aged <65 years without significant comorbidities
  • FMC (Fludarabine, Mitoxantrone, Cyclophosphamide)
    • Indicated for T-PLL followed by Alemtuzumab
  • Gemcitabine, Vinorelbine ± Rituximab
    • Treatment option in the 2nd-line and subsequent treatment of DLBCL
  • GemOx (Gemcitabine, Oxaliplatin) ± Rituximab
    • Recommended 2nd-line and subsequent treatment for patients with DLBCL, PTCL, ATLL and EKNL with Rituximab excluded
    • In combination with Pegaspargase with Rituximab excluded, is recommended in the induction therapy of EKNL
  • GDP (Gemcitabine, Dexamethasone, Cisplatin/Carboplatin) ± Rituximab
    • Recommended 2nd-line and subsequent treatment for patients with DLBCL, PTCL, ATLL and EKNL with Rituximab excluded
    • Recommended in the induction therapy of EKNL in combination with Pegaspargase (DDGP) excluding Rituximab
    • May be used in the 2nd-line treatment of BL in combination with Rituximab
  • GVD (Gemcitabine, Vinorelbine, liposomal Doxorubicin)
    • Recommended for 2nd-line and subsequent treatment of PTCL and ATLL
  • HMDP (High-dose Methylprednisolone) + Rituximab
    • Treatment option for all patients regardless of age and comorbidities with untreated CLL/SLL without del(17p)/TP53 mutation or with relapsed/refractory disease
    • Treatment option for patients with CLL/SLL with del(17p)/TP53 mutation
  • HyperCVAD (hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone) + Rituximab
    • May be used as induction therapy for patients with MCL and <60 year-old patients with BL, alternating with high-dose Methotrexate and Cytarabine + Rituximab, 1st-line alternative therapy for PTCL patients, and for patients with ATLL alternating with high-dose Methotrexate and Cytarabine
  • Ibrutinib, Lenalidomide, Rituximab
    • Treatment option for refractory/relapsed MCL
  • Ibrutinib + Obinutuzumab
    • Treatment option for CLL/SLL patients without del(17p)/TP3 mutation who are frail with significant comorbidities, intolerant of purine analogs or aged ≥65 years and younger with significant comorbidities
  • Ibrutinib + Rituximab
    • Recommended in the 2nd-line treatment of patients with MCL with short response duration to previous chemoimmunotherapy
    • Treatment option for CLL/SLL patients without del(17p)/TP53 mutation aged <65 years without significant comorbidities
  • ICE (Ifosfamide, Carboplatin, Etoposide) ± Rituximab
    • May be used in the 1st-line therapy of PMBL after RCHOP regimen, as 2nd-line and subsequent therapy for patients with DLBCL, as 2nd-line therapy for patients with BL in combination with Rituximab, and 2nd-line and subsequent therapy for PTCL, ATLL and EKNL with Rituximab excluded (ICE)
  • Idelalisib + Rituximab
    • Recommended for CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease who are frail with significant comorbidities or aged ≥65 years and younger with significant comorbidities or <65 years without significant comorbidities and for CLL/SLL patients with del(17p)/TP53 mutation with relapsed/refractory disease
  • Lenalidomide + Obinutuzumab
    • Treatment option in the 1st- and 2nd-line/subsequent treatment in patients with FL
  • Lenalidomide ± Rituximab
    • Recommended in the following:
      • For CLL/SLL patients with or without del(17p)/TP53 mutation with relapsed/refractory disease regardless of age and comorbidities
      • 1st- and 2nd-line/subsequent treatment of FL
      • For less aggressive induction and in the 2nd-line treatment of MCL
      • 2nd-line and subsequent treatment of MZL particulary in elderly and infirm patients who are intolerant of other treatment regimens
    • Treatment option in the 1st-line therapy of MZL and in the 2nd-line and subsequent treatment of patients with non-GCB DLBCL
  • MINE (Mesna, Ifosfamide, Mitoxantrone, Etoposide) ± Rituximab
    • Recommended 2nd-line and subsequent treatment for patients with DLBCL
  • Obinutuzumab + Chlorambucil
    • Treatment option as 1st line therapy for CLL/SLL patients without del (17p)/TP53 mutation who are frail with significant comorbidity, intolerant of purine analogs or ≥65 years and younger with significant comorbidities
  • Obinutuzumab + Venetoclax
    • Recommended 1st-line treatment for CLL/SLL patients without del(17p)/TP53 mutation who are intolerant to purine analogs or aged ≥65 years and younger with significant comorbidities and <65 years without significant comorbidities and for CLL/SLL patients with del(17p)/TP53 mutation
  • Polatuzumab vedotin ± Bendamustine ± Rituximab
    • Recommended in the 2nd-line and subsequent treatment of patients with DLBCL with ≥2 previous treatments
  • PCR (Pentostatin, Cyclophosphamide and Rituximab)
    • Treatment option for CLL/SLL patients without del(17p)/TP53 mutation aged <65 years without significant comorbidities, those with refractory/relapsed disease ≥65 years and younger with significant comorbidities (reduced-dose) and <65 years old without comorbidities
  • PEPC (Prednisone, Etoposide, Procarbazine, Cyclophosphamide) ± Rituximab
    • May be used as 2nd-line therapy in patients with MCL and as 1st-line, 2nd-line and subsequent therapy in patients with DLBCL and those with poor LV function
    • May also be used for frail patients intolerant of anthracycline with monomorphic and polymorphic PTLD
  • R-ACVBP (Rituximab, Cyclophosphamide, Doxorubicin, Vindesine, Bleomycin and Prednisone)
    • May be used for patients with aggressive stage I/contiguous stage II NHL
  • RBAC (Rituximab, Bendamustine, Cytarabine)
    • Treatment option for less aggressive induction of MCL
  • RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
    • Recommended in the 1st- and 2nd-line/subsequent treatment for patients with FL, MZL, in the 1st-line treatment of PMBL and DLBCL, and for concurrent chemoimmunotherapy of monomorphic and polymorphic PTLD
    • Recommended for aggressive induction therapy of patients with MCL, alternating with RDHAP, for less aggressive induction, and in the 2nd-line treatment of MCL
      • Dose-intensified RCHOP (maxi-CHOP) alternating with high-dose Cytarabine is recommended for aggressive induction of MCL
    • Treatment option for HGBL
    • Combination with liposomal Doxorubicin (RCDOP) may be used as 1st-line treatment in DLBCL patients with poor LV function, frail or aged >80 years old with comorbidities
    • Used for patients with aggressive stage I/contiguous stage II (4-6 cycles), indolent noncontiguous stage II/III/IV, and aggressive noncontiguous stage II/III/IV NHL
    • Studies recommend a regimen of 3-6 cycles in patients with aggressive stage I and contiguous stage II NHL when given with IF-XRT
    • Studies have shown better treatment response (increased event-free survival and overall survival) to R-CHOP as compared to CHOP in advanced-stage DLBCL >60 years
  • R-CVP (Rituximab, Cyclophosphamide, Vincristine, and Prednisone)
    • Recommended for patients with indolent noncontiguous stage II/III/IV NHL, and in the 1st- and 2nd-line/subsequent treatment of patients with FL and MZL
    • Treatment option for concurrent treatment of frail patients with monomorphic and polymorphic PLTD who are intolerant of anthracyclines
    • Addition of Gemcitabine (RGCVP) or Etoposide (RCEOP) to this combination may be used in patients as 1st-line treatment in DLBCL patients with poor LV function
      • RGCVP may also be used in patients >80 years old with comorbidities
      • RCEOP may be used as 2nd-line and subsequent therapy for patients with DLBCL and for concurrent treatment of frail patients with monomorphic and polymorphic PLTD who are intolerant of anthracyclines
  • RDHAP (Rituximab, Dexamethasone, Cytarabine) + platinum (Carboplatin, Cisplatin or Oxaliplatin)
    • Recommended for aggressive induction therapy of patients with MCL, alternating with RCHOP, as 2nd-line and subsequent therapy for patients with DLBCL, and 2nd-line and subsequent therapy for PTCL, ATLL and ENKL with Rituximab excluded (DHAP)
  • R-F (Rituximab + Fludarabine)
    • Recommended for patients with indolent noncontiguous stage II/III/IV NHL and treatment option for CLL/SLL patients without del (17p)/TP53 mutation aged <65 years without significant comorbidities
  • R-FCM (Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone)
    • Recommended for patients with indolent noncontiguous stage II/III/IV NHL
  • R-FM (Rituximab, Fludarabine and Mitoxantrone)
    • Used for patients with indolent noncontiguous stage II/III/IV NHL
  • RIVAC (Rituximab, Ifosfamide, Cytarabine, Etoposide)
    • May be used in the 2nd-line treatment of BL
  • SMILE (steroid [Dexamethasone], Methotrexate, Ifosfamide, Pegaspargase, Etoposide) (modified)
    • Recommended in the induction therapy of advanced stage EKNL
  • Venetoclax + Ibrutinib
    • Treatment option for refractory/relapsed MCL
  • Venetoclax + Rituximab
    • Recommended for CLL/SLL patients without del(17p)/TP53 mutation with relapsed/refractory disease who are frail with significant comorbidity or aged ≥65 years and younger with significant comorbidities or <65 years without significant comorbidities and patients with del(17p)/TP53 mutation with relapsed/refractory disease
  • VR-CAP (Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone)
    • Treatment option for less aggressive induction and in the 2nd-line treatment of MCL
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.